Ritract Ltd.

Ritract Receives FDA Clearance to Market in the United States

Sydney, Australia; 07 June 2006: Ritract Limited (ASX: RTL) today reported that the US Food &
Drug Administration (FDA) has given approval for the Company to begin marketing the Ritract
Safety Syringe Range in the United States.

Ritract Managing Director, Mr Rupert Northcott, said “this clearance to market now enables
Ritract to ship our first order for 500,000 Ritract Safety Syringes to B. Braun (Melsungen) AG in
the United States, which will generate initial revenues of more than A$300,000.”

Obtaining FDA clearance is a major milestone for Ritract, making it the first Australian auto-
retractable safety syringe company to be able to sell its products in the United States.

B. Braun can now begin its sales test in the US and Australia as a precursor to an anticipated
international sales and distribution agreement. B. Braun is one of the world’s largest medical
consumables companies with sales operations in more than 40 countries and annual revenues
exceeding $4 billion.
“With the potential to leverage B. Braun’s global distribution capability and the advantage of
being the first to market with a full product range of auto-retractable safety syringes, we believe
Ritract is well on track to capture significant market share worldwide,” Mr Northcott said.

Mr Northcott added Ritract understood it was the only company in the world with the:

• first commercially available automatic retractable syringe with the advantage that allows
use of standard needles versus syringe products with fixed needles or more costly
proprietary needle options
• first commercially available automatic retractable syringe that allows full user control of
the needle retraction as requested by clinicians versus uncontrolled needle retraction
offered by competitors
• first company with a full range of safety syringe sizes that allows use of standard
About Ritract

Ritract Limited’s patented unique technology is designed to meet world demand for innovative,
safety injection solutions in global health markets. Ritract's immediate markets are health care
workers at the front line of the international medical community, with the primary aim being to
protect them from needlestick injury. The company’s vision is to help create a safer world by
replacing every non-safety needle and syringe with Ritract safety technology.